Sinovac Biotech (SVA)
(Delayed Data from NSDQ)
$8.47 USD
0.00 (0.00%)
Updated Dec 31, 1969 06:00 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Sinovac Biotech, Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 448 | 1,493 | 19,375 | 511 | 246 |
Cost Of Goods | 182 | 684 | 1,072 | 67 | 32 |
Gross Profit | 267 | 808 | 18,303 | 443 | 214 |
Selling & Adminstrative & Depr. & Amort Expenses | 870 | 1,274 | 749 | 228 | 145 |
Income After Depreciation & Amortization | -603 | -466 | 17,553 | 216 | 69 |
Non-Operating Income | 452 | 493 | 13 | 2 | 3 |
Interest Expense | 2 | 1 | 3 | 1 | 1 |
Pretax Income | -153 | 25 | 17,563 | 217 | 71 |
Income Taxes | 105 | -63 | 3,104 | 31 | 6 |
Minority Interest | -158 | -26 | 5,991 | 75 | 20 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -258 | 88 | 14,459 | 185 | 65 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -100 | 114 | 8,467 | 110 | 45 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -461 | -311 | 17,638 | 219 | 73 |
Depreciation & Amortization (Cash Flow) | 143 | 155 | 85 | 4 | 5 |
Income After Depreciation & Amortization | -603 | -466 | 17,553 | 216 | 69 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 99.61 | 114.17 | 114.01 | 113.66 | 109.69 |
Diluted EPS Before Non-Recurring Items | -1.32 | -0.37 | 74.67 | 1.03 | 0.41 |
Diluted Net EPS (GAAP) | -1.06 | 1.00 | 74.27 | 0.97 | 0.41 |
Fiscal Year end for Sinovac Biotech, Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |